Gritstone bio, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2022 | $45 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Sep 2021 | $55 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Gritstone bio, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2022).
SEC Form D · Nov 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2022
That is all the official record says: Gritstone bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
10 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Clarus Lifesciences III, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Clarus Ventures III GP, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Clarus Ventures III, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Column Group II GP, LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock (Form 3, 2018) | SEC Form 3 |
| Column Group II, LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Redmile Group, LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Versant Affiliates Fund V, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Versant Ophthalmic Affiliates I, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Versant Venture Capital V (Canada), LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Versant Venture Capital V, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 10 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew Allen | Executive officer | Nov 2022 |
| Andrew E. Allen | Executive officer | Nov 2022 |
| Erin E. Jones | Executive officer | Nov 2022 |
| Karin E. Joos | Executive officer | Nov 2022 |
| Matthew Hawryluk | Executive officer | Nov 2022 |
| Vassiliki Economides | Executive officer | Nov 2022 |
| Andrew Allen, M.D., Ph.D. | President and Chief Executive Officer | Oct 2021 |
| Celia Economides | Chief Financial Officer | Oct 2021 |
| Erin Jones | Chief Operating Officer | Oct 2021 |
| James Cho | Chief Accounting Officer | Oct 2021 |
| Karin Joos | Head of Research and Development | Oct 2021 |
| Matt Hawryluk | Executive Vice President, Chief Business Officer | Oct 2021 |
| Rahsaan Thompson, J.D. | Executive Vice President and General Counsel | Oct 2021 |
| Andrew Allen | Director | Nov 2022 |
| Andrew E. Allen | Director | Nov 2022 |
| Clare A. Fisher | Director | Nov 2022 |
| Elaine E. Jones | Director | Nov 2022 |
| Lawrence E. Corey | Director | Nov 2022 |
| Naiyer A. Rizvi | Director | Nov 2022 |
| Shefali E. Agarwal | Director | Nov 2022 |
| Steve A. Krognes | Director | Nov 2022 |
| Andrew Allen, M.D., Ph.D. | President and Chief Executive Officer | Oct 2021 |
| Elaine Jones, Ph.D. | Director | Oct 2021 |
| Judith Li | Director | Oct 2021 |
| Naiyer Rizvi, M.D. | Director | Oct 2021 |
| Richard Heyman, Ph.D. | Director | Oct 2021 |
| Shefali Agarwal, M.D., M.P.H. | Director | Oct 2021 |
| Steve Krognes | Director | Oct 2021 |